IAMA Therapeutics

At IAMA Therapeutics, a series-A pharmaceutical company, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families with the support they need. We have developed a platform to identify and advance diverse classes of small molecules to selectively target cation chloride cotransporters (CCCs) and other therapeutic targets relevant to treating central nervous system disorders. NKCC1 mediates the coupled movement of chloride with potassium and sodium across the cell membrane with essential roles in physiological processes, including modulating neuronal excitability. High NKCC1 activity contributes to maintaining an elevated intracellular chloride concentration such that GABA (γ-aminobutyric acid), the principal inhibitory neurotransmitter in mature neurons under physiological conditions, stimulates chloride efflux and produces depolarizing and excitatory outward currents in immature neurons. The activity of NKCC1 increases also in several pathological conditions; this is why NKCC1 inhibition shows great potential in treating idiopathic and secondary forms of autisms (autism spectrum disorder -ASD-), refractory epilepsy, and other neurological disorders. We understand our job responsibilities and recognize the value of our actions in everything we do. This is why our core values root in excellence, innovation, integrity, equality, respect for diversity, and sustainability of our future generations.